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Abstract
Previous studies have shown that the dual phosphatidylinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR)
inhibitor NVP-BEZ235 radiosensitizes tumor cells if added shortly before ionizing radiation (IR) and kept in culture
medium thereafter. The present study explores the impact of inhibitor and IR schedule on the radiosensitizing ability
of NVP-BEZ235 in four human glioblastoma cell lines. Two different drug-IR treatment schedules were compared. In
schedule I, cells were treated with NVP-BEZ235 for 24 hours before IR and the drug was removed before IR. In schedule II,
the cells were exposed to NVP-BEZ235 1 hour before, during, and up to 48 hours after IR. The cellular response was
analyzed by colony counts, expression of marker proteins of the PI3K/AKT/mTOR pathway, cell cycle, and DNA damage.
We found that under schedule I, NVP-BEZ235 did not radiosensitize cells, whichweremostly arrested in G1 phase during
IR exposure. In addition, the drug-pretreated and irradiated cells exhibited less DNA damage but increased expressions
of phospho-AKT and phospho-mTOR, compared to controls. In contrast, NVP-BEZ235 strongly enhanced the radiosen-
sitivity of cells treated according to schedule II. Possible reasons of radiosensitization by NVP-BEZ235 under schedule II
might be the protracted DNA repair, prolonged G2/M arrest, and, to some extent, apoptosis. In addition, the PI3K path-
way was downregulated by the NVP-BEZ235 at the time of irradiation under schedule II, as contrasted with its activation
in schedule I. We found that, depending on the drug-IR schedule, the NVP-BEZ235 can act either as a strong radiosen-
sitizer or as a cytostatic agent in glioblastoma cells.
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Introduction
Glioblastoma multiforme is the most aggressive primary brain tumor
in adults. Standard therapy includes surgical resection followed by
radiotherapy, which significantly prolongs survival [1]. Chemotherapy
added to radiotherapy is used as concurrent or adjuvant treatment.
Although more long-term survivors have been reported after combined
chemoradiotherapy [2–4], its success is limited in patients who develop
chemoresistance. The induction of chemoresistance is commonly asso-
ciated with the activation of cell survival pathways and/or aberrations
in tumor suppressor genes (for reviews, see [5,6]). Among various
survival pathways, the phosphatidylinositide 3-kinase (PI3K)/AKT/
mammalian target of rapamycin (mTOR) pathway (hereafter denoted as
the PI3K pathway) plays a crucial role in oncogenesis and tumor cell-
growth [7]. Its activation can contribute to resistance(s) to chemotherapy
and/or radiotherapy by promoting cell survival through prevention of
apoptosis [8–11]. Therefore, inhibition of the key proteins in this path-
way, such as PI3K, AKT, and/or mTOR, can lead to sensitization of
various tumor cell lines to ionizing radiation (IR) [12–17]. A number
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of pharmacological inhibitors of the PI3K pathway are known to syner-
gistically enhance the cytotoxicity of IR [13–15,17,18]. Examples of the
single-target inhibitors of the first generation are LY294002 [18] and
wortmannin [14] (both inhibitors of PI3K), as well as themTOR inhib-
itor rapamycin [17], which have been shown to enhance the radiation
sensitivity of several tumor cell lines. A major drawback of the single-
target inhibitors (either PI3K or mTOR), however, is the induction
of a feedback loop resulting in a compensatory stimulation of AKT,
which in turn activates pro-survival signaling [19–21]. Moreover, some
of the first-generation inhibitors have revealed low specificity, instability,
or insolubility (reviewed in [22]) and have also caused severe side effects
in mouse model, such as respiratory depression and lethargy [23].
There has been considerable effort to design small synthetic in-
hibitors of the PI3K pathway with improved selectivity and pharma-
ceutical properties. Both requirements are met by NVP-BEZ235, an
imidazoquinoline derivate, which simultaneously inhibits pan-class I
PI3K and mTOR kinases [24]. This novel orally available dual
PI3K and mTOR inhibitor has revealed potent antitumor activity in
several in vitro and in vivo studies [25–28]. In addition, the substance
enhances the radiation sensitivity of several tumor cell lines in vitro
[29–33] as well as in tumor model in vivo [29,32,33]. According to
the studies quoted above [29,30,32,33], NVP-BEZ235 exerts radio-
sensitizing antitumor effects if it is added to tumor cells shortly before
irradiation and cells are kept in drug-containing medium for up to
24 hours after irradiation. In contrast, Fokas et al. have found no
radiosensitization of laryngeal SQ20 and bladder T24 tumor cell lines
if NVP-BEZ235 was added 6 hours after IR for a total exposure time
of 18 hours [21].
To prove whether the time schedule of NVP-BEZ235 and IR
administration is critical for radiosensitization, we explore in the pres-
ent study the response of four established glioblastoma cell lines to two
different drug-IR schedules. In schedule I, tumor cells were incubated
with the drug for 24 hours, but shortly before IR the substance was
washed out. In schedule II, the inhibitor was added to the cells 1 hour
before IR and kept in culture medium up to 48 hours after IR. Cells
treated according to the different drug-IR schedules were analyzed for
colony-forming ability, induction and repair of radiation-induced
DNA damage, and cell cycle distribution. In addition, the expression
levels of several marker proteins (PTEN, PI3K, AKT, phospho-AKT,
mTOR, phospho-mTOR, phospho-4E-BP1, S6, phospho-S6 ribosomal
protein, etc.) were assessed by Western blot analysis.
Materials and Methods
Cells
The group of human glioblastoma cell lines examined includes
GaMG (PTEN wt, p53 mut), DK-MG (PTEN wt, p53 wt), U373
(PTEN mut, p53 mut), and U87-MG (PTEN mut, p53 wt) cells.
All cell lines were obtained from the American Type Culture Collec-
tion (Manassas, VA) and routinely cultured under standard conditions
(5% CO2, 37°C) in complete growth medium (CGM), which was
either Dulbecco’s modified Eagle’s medium (GaMG, DK-MG) or
minimum essential medium (U373, U87-MG), supplemented with
10% FBS.
Drug Treatment
The dual PI3K and mTOR inhibitor NVP-BEZ235 [24] was
kindly provided by Novartis Institutes for Biomedical Research (Basel,
Switzerland). The drug was freshly diluted from frozen aliquots in
DMSO stored at −20°C. Drug (100 nM) and radiation treatments
were applied in two different schedules (Figure 1). In schedule I, the
substance was added 24 hours before IR and washed out shortly before
irradiation. Under schedule II, the drug was added 1 hour before IR
and remained in CGM up to 48 hours after IR. Cells treated in parallel
with respective amounts of DMSO served as controls.
Antibodies
The primary and secondary antibodies are specified in Supple-
mentary Materials.
Cell Viability Assay
The intracellular ATP level, as an indicator of cell viability, was
determined by means of the CellTiter-Glo Luminiscent Cell Viability
Assay (Promega, Madison, WI) according to the manufacturer’s
instructions. Serial dilutions of NVP-BEZ235 (0–5 μM) in CGMwere
added to cell cultures in quadruplicates and the cytotoxicity of the drug
was determined 24 and 48 hours later. Control samples contained the
respective concentrations of DMSO. The mean ATP content data
(±SD) from three independent experiments were normalized against
DMSO-treated controls to generate dose-response curves and then
analyzed with the standard four-parameter logistic model (4PLM,
Equation 1):
Y =
A1 − A2
1 + ðc = IC50Þp + A2; ð1Þ
where Y is the cell viability, c is drug concentration given in nM, A1
and A2 are the upper and lower asymptotes, respectively, IC50 is the
50% inhibitory concentration (nM), and p is the Hill slope.
Colony Survival Assay
Cell survival curves were generated by a standard colony formation
assay as previously described [34]. Subconfluent monolayers of drug-
treated and non-treated cells were irradiated in culture flasks filled
with CGM at room temperature by graded single doses (0–8 Gy),
seeded either immediately (schedule I) or 24 hours (schedule II) after
IR in Petri dishes and then cultivated in CGM for the next 2 weeks.
Four replications were carried out for each exposure point, and the
Figure 1. Two different drug-IR schedules were used in this study.
Schedule I: NVP-BEZ235 was added to the tumor cell cultures for
24 hours and washed out shortly before IR. Schedule II: NVP-
BEZ235 was added to the cell cultures 1 hour before IR and kept
in culture medium up to 48 hours after IR. Cells treated in different
schedules were then analyzed by colony-forming ability, expression
of marker proteins, DNA damage, and cell cycle progression.
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experiments were repeated at least twice. After 2 weeks, the cells were
fixed and stained with crystal violet (0.6%). Colonies of at least 50 cells
were scored as survivors. The mean survival data for each individual cell
line were fitted to the linear quadratic (LQ) model (Equation 2):
SF = exp −αX − βX 2
 
; ð2Þ
where SF is the survival fraction, X is the irradiation dose, and α and
β are the fitted parameters.
Western Blot
For immunoblot analysis, whole-cell lysates were prepared accord-
ing to standard procedures. Samples equivalent to 20 to 40 μg of
protein were separated using 4% to 12% sodium dodecyl sulfate–
polyacrylamide pre-cast gels (Invitrogen, Karlsruhe, Germany) and
transferred to nitrocellulose membranes. For protein detection, mem-
branes were incubated with respective primary and species-specific
peroxidase-labeled secondary antibodies according to standard protocols.
The levels of protein expression were quantified using the Kodak 1D
Image analyzing software (Scientific Imaging Systems, Eastman Kodak
Company, Rochester, NY) and normalized to the β-actin levels.
X-ray Irradiation
Irradiation was performed at room temperature using a 6-MV
Siemens linear accelerator (Siemens, Concord, CA) at a dose rate
of 2 Gy/min. After irradiation, cells were kept in CGM for the
indicated time until harvest.
Detection of Histone γH2AX and Cell Cycle Measurements
by Flow Cytometry
Non-treated and drug-treated cell cultures were irradiated as sub-
confluent monolayers in CGM at room temperature. The cells were
then incubated under standard conditions and analyzed by flow cyto-
metry 30 minutes, 24 hours, and 48 hours after IR exposure. For
analysis, cells were trypsinized, washed twice in phosphate-buffered
saline, fixed, and stained for γH2AX according to a protocol described
elsewhere [35]. The cells were then counterstained with propidium
iodide (PI, Sigma P-4170, 10 μg/ml) in the presence of RNase A
(Sigma R-5250, 25 μg/ml) as described elsewhere [36]. At least
15,000 cells were assayed for either histone γH2AX, DNA distribu-
tion, or fraction of cells with hypodiploid DNA content using a flow
cytometer FACSCalibur (Becton Dickinson, San Jose, CA) equipped
with a 15-mW argon-ion laser. Cellular green (histone γH2AX) or
red fluorescence (DNA-PI) was acquired in logarithmic or linear
mode, respectively. The output data presented as one-dimensional
histograms, i.e., the distributions of histone γH2AX or PI-DNA sig-
nals within cell samples, were analyzed using the Flowing Software
program obtained from P. Terho (Turku Centre for Biotechnology,
Turku, Finland) and the ModFit LT program (Verity Software House,
Topsham, ME).
Statistics
Data are presented as means (±SD or ±SE). Mean values were com-
pared by the Student’s t test. The threshold of statistical significance
was set at P < .05. Statistics and fitting of experimental data were
performed with Origin 8.5 (Microcal, Northampton, MA).
Results
Effects of NVP-BEZ235 on Cell Proliferation and
Colony Survival
The cytotoxic potential of NVP-BEZ235 against non-irradiated
tumor cells was studied over a concentration range from 10 nM to
1 μM. Cell viability was quantified by an ATP-based assay. The cellular
ATP levels in drug-treated samples were normalized against DMSO-
treated controls, plotted versus the drug concentration (Figure W1),
and fitted to the 4PLM (Equation 1). As seen in Figure W1, the ATP
content in four tested cell lines depends not only on drug concen-
ration but also on the duration of drug treatment. With increasing
NVP-BEZ235 concentration, the mean ATP content in all cell lines
decreased steadily to reach a plateau at about 60% to 70% and 40%
to 50% of the initial level after a 24-hour and a 48-hour drug exposure,
respectively. In all cell lines, the maximumATP inhibition was achieved
at NVP-BEZ235 concentrations ≥100 nM. On the basis of these
measurements, a drug concentration of 100 nM was used for sub-
sequent experiments. The selected inhibitor concentration is consistent
with the previously reported data [24,37].
Using the colony survival assay, we analyzed in the following ex-
periments the radiation sensitivities of glioblastoma cells treated with
NVP-BEZ235 according to two different drug-IR schedules presented
schematically in Figure 1. Figure 2 shows the normalized cell survival
responses of drug-treated cells plotted versus the radiation dose, along
with the best fits of the LQmodel (Equation 2) to the data. The plating
efficiencies (PEs) of non-irradiated cell samples, as well as the fitted
parameters derived with the LQ model, including the surviving frac-
tion at 2 Gy (SF2), the radiation dose required to reduce colony form-
ing ability by 90% (D10), and the growth inhibition factor (I10), are
summarized in Table W1.
The data shown in Figure 2 and TableW1 prove that NVP-BEZ235
did not affect the radiosensitivity of glioblastoma cells treated accord-
ing to schedule I. At the same time, NVP-BEZ235 acted as a potent
radiosensitizer in all tested cell lines treated with schedule II (Figure 2,
bottom row), which is also evident from the markedly reduced SF2 and
D10 values (Table W1) in drug-treated samples. The radiosensitizing
activity of NVP-BEZ235 in glioblastoma cell lines was independent
of their PTEN and p53 mutational status.
Changes in the PI3K Pathway Induced by NVP-BEZ235
and/or Radiation
To elucidate the molecular basis for the distinct radiation responses
of tumor cells treated with different drug-IR schedules (Figure 2), we
analyzed the expression of several marker proteins of the PI3K pathway
by Western blot analysis. Figure 3 shows exemplarily the Western blot
data of control and drug-treated DK-MG and U87-MG cells probed
for PTEN, PI3K (110 and 85 kDa), phospho-AKT, AKT, phospho-
mTOR, mTOR, phospho-S6, and phospho-4E-BP1 30 minutes after
irradiation with 8 Gy. Samples shown on the left- and right-hand sides
of Figure 3 were treated according to schedules I and II, respectively.
The data for the other tested cell lines at 30 minutes are shown in
Figure W2. The expressions at 24 and 48 hours after IR are shown
in Figures W3 and W4, respectively.
As expected, PTEN protein was detected only in DK-MG cells
that are wild-type PTEN, whereas the PTEN mutated U87-MG cell
line showed no expression of PTEN at all (Figure 3). Furthermore,
the background expression levels of phospho-AKT and phospho-
mTOR in U87-MG cells were much higher than in DK-MG cells,
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which can be associated with the lack of PTEN in U87-MG cells
leading to a compensatory activation of the PI3K pathway.
In non-irradiated DK-MG cells treated with schedule I, NVP-
BEZ235 caused a moderate increase of p110α subunit of PI3K and
also two-fold increases of phospho-AKT (0.26→0.55 a.u.) and
phospho-mTOR (0.33→0.67 a.u.; Figure 3A). At the same time,
treatment of U87-MG cells using schedule I without IR induced
almost no changes in the expression of all tested proteins, except
for phospho-AKT whose expression slightly increased from 1.06
to 1.24 a.u. In contrast, treatment of cells according to schedule II
strongly reduced the expressions of phospho-AKT and phospho-
mTOR after a short (1 hour) incubation with NVP-BEZ235 in both
cell lines, with or without radiation. Two other tested cell lines, GaMG
and U373, showed qualitatively similar data on the expression of
marker proteins detected 30 minutes or 24 and 48 hours (Figures W2–
W4) after IR.
We also analyzed the expression of ribosomal S6 and translational
repressor 4E-BP1 proteins, which are downstreams of mTOR known
to influence cell cycle progression and growth regulation [38,39].
Thirty minutes after IR under schedule I (Figures 3 and W2, left
panel), phospho-S6 protein was completely suppressed in drug-
pretreated cells but mostly recovered to the normal level after wash-
ing out NVP-BEZ235 (Figures W3 and W4, A and B). In contrast,
treatment of cells with NVP-BEZ235 according to schedule II
altered the expression of phospho-S6 protein immediately (30 min-
utes) after irradiation to a much lesser extent (Figures 2 and W2, right
side) than under schedule I. However, at 24 and 48 hours after IR,
this protein was nearly depleted under schedule II (Figures W3
and W4, right side). The expression of phospho-4E-BP1 remained
almost unchanged in cells treated according to schedule I throughout
the experiment (i.e., 30 minutes to 48 hours after IR). In contrast,
the addition of NVP-BEZ235 according to schedule II led to a
strong depletion of phospho-4E-BP1 over the whole observation time
(30 minutes to 48 hours).
Assessment of Late-Stage Apoptosis
Further efforts to identify the mechanism(s) of radiosensitizing
effects of NVP-BEZ235 on glioblastoma cells seen under schedule II
were made by measuring late-stage apoptosis using flow cytometry.
Figure 4 shows exemplarily the DNA content distributions in GaMG
cells treated with NVP-BEZ235 and IR according to schedules I and II
analyzed by flow cytometry 24 and 48 hours after irradiation with
8 Gy. From the DNA histograms, the fractions of hypodiploid cells
were evaluated to assess the extent of late-stage apoptosis. As seen
in Figure 4 (right hand side, bottom row), combined drug-IR treat-
ment according to schedule II significantly increased the portion of
Figure 2. Clonogenic survival of glioblastoma cell lines treated with NVP-BEZ235 and irradiated either in schedule I (top row) or schedule II
(bottom row); for details on treatment, see Figure 1. Irradiated cells were plated for the colony-forming test either immediately after IR
(top row) or 24 hours after IR (bottom row). After 2 weeks, colonies containing at least 50 cells were scored as survivors. Data derived from
at least four independent experiments for each cell line and schedule were pooled together and fitted by an LQ equation (Equation 2). The
SD values are indicated by error bars.
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hypodiploid GaMG cells up to 54%, compared to the 9.6% detected in
control irradiated cells. Qualitatively similar results were obtained with
DK-MG and U373 cells but not with U87-MG cells (FigureW5). The
increased fraction of hypodiploid cells and debris in GaMG, DK-MG,
and U373 cells was found to correlate with the increased level of cleaved
poly (ADP-ribose) polymerase (PARP) an established pro-apoptotic
marker, in these cell lines (Figures W2–W4). Unlike schedule II, drug-IR
treatment according to schedule I did not induce apoptosis in GaMG
cells, as suggested by the nearly unchanged fraction of hypodiploid cells
(∼10%; Figure 4, third row) with respect to drug-free control (∼8%).
Induction and Decay of Histone γH2AX
The degree of DNA damage induced in glioblastoma cell lines by
two different drug-IR treatment schedules was assessed by immuno-
staining and flow cytometric detection of histone γH2AX, a sensitive
marker of DNA double-strand breaks [40]. The expression of histone
γH2AX was determined 30 minutes, 24 hours, and 48 hours after
irradiation (Figures 5A and W6, A–C ).
As evident from Figures 5A and W6, A to C (top rows), the
radiation-induced DNA damage in glioblastoma cells was only little,
if at all, affected by NVP-BEZ235 when cells were treated accord-
ing to schedule I. Moreover, 30 minutes after IR under schedule I,
the drug-IR treated GaMG cells exhibited even less DNA damage
(69 a.u. of γH2AX; Figure 5A) than the corresponding irradiated
drug-free controls (101 a.u.). As with the initial IR-induced DNA
damage, NVP-BEZ235, given under schedule I, did not noticeably
affect the DNA damage repair process in glioblastoma cell lines, as
suggested by the rapid reduction of γH2AX observed 24 and 48 hours
after IR (middle and bottom rows in Figure 5A).
Under schedule II, NVP-BEZ235 increased nearly four-fold the
initial IR-induced DNA damage in GaMG cells (43→169 a.u.
of γH2AX), compared to a 3.4-fold increase in drug-free control
(66→226 a.u.). Among the four cell lines, a drug-mediated induction
of DNA damage under schedule II also occurred in DK-MG and U373
cells (Figure W6, A and C ) but was less evident in U87-MG cells
(Figure W6B). Despite lower or similar initial damage, the DNA
damage repair was severely impaired in all glioblastoma cell lines treated
with NVP-BEZ235 according to schedule II, compared to drug-free
controls and also to schedule I.
Prompted by the observation that drug-IR treatment under sched-
ule II increased DNA damage and impaired its repair, we analyzed the
expression of the DNA repair protein Rad51. Recently, the expres-
sion of this protein has been found to be abrogated by NVP-BEZ235
[32]. Figure 5B shows representative Western blot detections of Rad51
protein in DK-MG and U87-MG cell lines treated with two dif-
ferent drug-IR schedules. In agreement with [32], we found that
NVP-BEZ235 strongly inhibited the expression of Rad51 protein
(Figure 5B). Thus, with increasing incubation time with NVP-
BEZ235 from 30 minutes to 48 hours under schedule II, the Rad51
contents decreased steadily from 0.73 to 0.13 a.u. in non-irradiated
DK-MG cells and from 1.05 to 0.33 a.u. in non-irradiated U87 cells.
Combined drug-IR treatment caused further depletion of Rad51 in
U87 cells (but not in DK-MG).
Figure 3. Representative Western blot analysis of expression levels of several marker proteins of the PI3K pathway. DK-MG (A, C) and
U87-MG (B, D) tumor cell lines were subjected to drug and IR treatments according schedule I (A, B) or schedule II (C, D). Cellular lysates
were prepared 30 minutes after irradiation with 8 Gy. Each protein band was normalized to the intensity of β-actin used as loading
control, and the ratios are denoted by the numbers if significant changes in the expression are present. The experiment was repeated
at least three times. n.d. indicates not determined.
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Cells treated with schedule I (i.e., a 24-hour preincubation with
NVP-BEZ235) also displayed low levels of Rad51 (0.31 a.u. in
DK-MG and 0.18 a.u. in U87-MG). However, 24 hours after washing
out the inhibitor, the expression of Rad51 returned back to the control
levels of 0.73 and 0.81 a.u. in DK-MG and U87 cells, respectively.
Qualitatively similar results were obtained with GaMG and U373 cell
lines. The expression of another tested DNA repair protein Rad50 was
not affected by NVP-BEZ235 treatment (data not shown).
Effects of NVP-BEZ235 and IR on Cell Cycle Progression
Further efforts to identify the mechanisms underlying the radio-
sensitizing effect of NVP-BEZ235 used only under schedule II and
Figure 4. Percentage of cells with hypodiploid DNA content and cellular debris in drug-treated and irradiated GaMG tumor cell line
measured flow cytometrically. Cells were subjected to drug-IR treatments according to schedule I (gray histograms) or schedule II (black
histograms). Unfilled histograms represent control drug untreated cells. Twenty-four or 48 hours after IR, the cells were detached with
trypsin, treated with saponin and RNAse, stained with PI, and then analyzed for red fluorescence by flow cytometry. The samples in-
clude both floating and trypsinized cells. Depicted are the percentages of events for hypodiploid nuclei and debris, computed by means
of the Flowing Software. The results are representative of three independent experiments.
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not under schedule I were focused on the possible impact of the drug
on cell cycle progression. Figure 6 shows representative cell cycle
histograms for DK-MG cells, whereas the summarized data for all
tested cell lines are shown in Tables W2–W4. The large portions
of cells in the S and G2/M phases (G2/G1 ratio of ∼0.6) in untreated
cells in Figure 6 (top row) prove that the cell culture was in the
exponential growth phase at the beginning of the experiments. A
24-hour incubation with NVP-BEZ235 under schedule I caused
an enrichment (up to 70%) of G1 cells, whereas the G2/G1 ratio sank
to ∼0.25. Upon washing out the drug, the cells were released from
the G1 block, and the G2/G1 ratio increased to ∼0.6 (Figure 6,
fourth row, left histogram).
Independent of the treatment schedule, irradiation with 8 Gy
resulted in an accumulation of cells in the G2/M phase of the cell cycle
Figure 5. Representative distributions of nuclear histone γH2AX (A) in GaMG glioblastoma cell line, detected 30 minutes, 24 hours, and
48 hours after irradiation with 8 Gy and after a combined drug-IR treatment either according schedule I (two top rows) or schedule II (third
and fourth rows) by means of flow cytometry. Black and light gray histograms represent irradiated and non-irradiated cells, respectively.
Numbers denote the mean histone γH2AX expression for the respective cell sample. Expression levels of the DNA repair protein Rad51
(B) detected in DK-MG and U87-MG cell lines treated in different drug-IR schedules. The experiment was repeated four times.
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24 hours after IR (Figure 6). Combined drug-IR treatment under
schedule II showed strong depletion of S phase cells (13%) compared
with that in schedule I (32%). Forty-eight hours after IR, combined
drug-IR treatment strongly depleted (by a factor of 3–4) the fraction
of S phase cells, under both treatment schedules. However, the arrest
under schedule I was reversible and the cell cycle normalized 48 hours
after IR. In contrast, under schedule II, the G2/M arrest persisted up
to 48 hours after IR.
To sum up, pretreatment with NVP-BEZ235 under schedule I
caused a G1 arrest before IR, which was reversible upon drug with-
drawal. Combined NVP-BEZ235 and IR treatment caused a strong
G2/M arrest 24 hours after IR in both schedules; under schedule II,
the arrest was prolonged up to 48 hours after IR.
Discussion
Clinicians have combined chemotherapy and radiation therapy since
the 1980s [41] and the combination of radiation and concurrent
chemotherapy or molecularly targeted therapy has been convincingly
shown to be superior to radiation alone in treatment of several can-
cer forms [42]. Among other factors, the efficacy of the combined
radiochemotherapy is dependent on the schedule of drug adminis-
tration [42]. Particularly, the combination of gemcitabine followed
Figure 6. Effects of NVP-BEZ235, ionizing radiation (IR), and combined drug-IR treatment on the cell cycle phase distribution in DK-MG
cell line. Cells were subjected to combined drug-IR treatment according schedule I (first and second columns from the left) or schedule II
(third and fourth columns). After IR with 8 Gy, cells were cultured for 30 minutes, 24 hours, or 48 hours, fixed, permeabilized, stained with
PI, and analyzed for DNA content by flow cytometry using linear signal amplification. DNA histograms were deconvoluted with ModFit
Software. Numbers denote the percentage of cells in G1, S, and G2/M phases and G2/G1 ratios in each cell sample. The data are represen-
tative of at least five independent experiments.
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by gefitinib (an inhibitor of the epidermal growth factor receptor) has
been found be more effective in controlling tumor growth than the
reverse drug schedule [42].
The present study was designed to prove whether the schedule of
NVP-BEZ235 and IR administration is critical for radiosensitization.
A major new finding of this study was that, depending on the drug-
IR schedule, the dual PI3K/mTOR inhibitor NVP-BEZ235 pro-
moted either radiosensitization or a cytostatic effect in glioblastoma
cell lines. The drug acted as a potent radiosensitizer only if added to
cells shortly before IR and kept in culture up to 24 hours thereafter
(schedule II), as evidenced by the colony counts shown in Figure 2
(bottom row). The radiosensitizing effect was independent of the
PTEN and p53 status of the cell lines. The enhancement of radiation
sensitivity by NVP-BEZ235 under schedule II reported here is con-
sistent with the recent findings that, if added shortly before IR,
NVP-BEZ235 radiosensitizes various tumor cell lines [29–33]. At
variance with schedule II, a long-term pretreatment of cells with
NVP-BEZ235 (schedule I) completely abolished the radiosensitizing
ability in all of tested glioblastoma lines (Figure 2, top row).
To elucidate the dependence of the radiosensitizing activity of
NVP-BEZ235 on the drug-IR schedule, we thoroughly examined
the expression of several key proteins of the PI3K pathway, the de-
gree of late-stage apoptosis, induction and repair of DNA damage,
and cell cycle distribution. The observed differences between cellular
responses to combined drug-IR treatment used under two different
schedules can be explained by a simplified model illustrated in Fig-
ure 7. The model takes account of the different expression of marker
proteins of the PI3K/mTOR pathway (Figures 3 and W2–W4), which
was dependent on the incubation time with the drug. The model
also includes additional data on the colony counts, DNA damage,
and cell cycle-progression given in Figures 2, 5, 6, and W2 to W6 and
Tables W1 to W4.
Surprisingly, our Western blot analysis revealed that the long-term
pretreatment with NVP-BEZ235 according to schedule I caused an
up-regulation of the phosphorylated forms of AKT and mTOR (Fig-
ure 7A) in three of four cell lines studied here (Figures 3 and W2). The
effect was even stronger after combined drug-IR treatment. The in-
creased expression of phospho-AKT and phospho-mTOR suggests
Figure 7. A simplified diagram of putative signaling pathways accountable for the differential responses of tumor cells to a dual PI3K/
mTOR inhibition and ionizing radiation (IR) used in two different drug-irradiation schedules. Incubation of tumor cells with NVP-BEZ235
for 24 hours before IR (A) leads to an activation of the PI3K/AKT/mTOR pathway at the time of irradiation, most likely due to the inhibition
of the negative feedback loop mediated by ribosomal protein S6 (Figures 3 and W2). Subsequently, the activated pro-survival kinase AKT
prevents radiation-induced apoptosis. In contrast, under schedule II, AKT and mTOR are suppressed at the time of irradiation (B). Fur-
thermore, incubation with NVP-BEZ235 for 24 hours causes an arrest in the G1 phase (Figure 6 and Tables W2–W4). Due to the higher
portion of G1 phase cells, exposure to IR leads to a diminished induction of γH2AX in cells treated for 24 hours before IR, compared to
controls and schedule II (Figures 5A and W6, A–C ). Cells treated according schedule I show a reduced Rad51 level during IR. After drug
removal, Rad51 returned to the normal level (Figure 5B), thus leading to full repair of DNA damage (Figures 5A and W6, A–C ). In contrast,
under schedule II the expression of Rad51 remained diminished 24 and 48 hours after IR (Figure 5B). This might have increased the
fraction of cells with hypodiploid DNA content and protracted DNA damage repair (Figures 4, W5, and 6). Besides this, cells treated
according to schedule II showed a strong G2/M arrest after combined drug-IR treatment (Figure 6 and Table W4). To summarize, sched-
ule I caused a cytostatic effect, whereas schedule II gave rise to a strong radiosensitization (take note of the size of the letters/symbols
and the thickness of the lines).
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the interruption of the negative feedback loops that downregulate
PI3K signaling, which in turn can paradoxically promote cell survival,
as reported in case of rapalogs elsewhere [43–45]. This mechanism
would explain the lack of radiosensitization by NVP-BEZ235 used
in schedule I (i.e., long-term pretreatment).
In contrast to schedule I, tumor cells exposed only briefly to NVP-
BEZ235 under schedule II exhibited reduced expression of phospho-
AKT and phospho-mTOR (Figure 7B) after irradiation and, to a
lesser extent, without IR exposure. Consistent with this observation,
simultaneous drug-IR treatment according to schedule II caused late-
stage apoptosis in DK-MG, GaMG, and U373 cell lines as evidenced
by the increased fractions of cells with hypodiploid DNA content
and cellular debris (Figures 4 and W5). In agreement with our data,
Fokas et al. have found that NVP-BEZ235 increased both apoptosis
and necrosis in SQ20B cells, without inducing apoptosis in FaDu
cells [31]. Several studies have shown cell type–specific induction of
apoptosis by NVP-BEZ235. Thus, NVP-BEZ235 has induced
apoptosis in lung carcinoma, sarcoma, and leukemia [29,46] but
not in glioma cell lines [47,48].
A further critical determinant of radiation-induced cell death is the
induction and repair of DNA double-strand breaks, probed in this
study by the expression of histone γH2AX (Figures 5 and W6, A–C).
We found that the kinetics of DNA damage repair differed markedly
between two treatment protocols. In cell samples pretreated with the
NVP-BEZ235 under schedule I, the DNA damage completely recov-
ered 48 hours after IR. In contrast, cells treated according schedule II
showed high residual DNA damage levels up to 48 hours after IR,
probably because of the NVP-BEZ235–mediated impairment of the
homologous recombination mechanism of DNA repair.
In addition to the above effects, long-term treatment with NVP-
BEZ235 before IR (schedule I) caused a substantial G1 arrest. As a
result, irradiation of G1-arrested cells under schedule I induced even
less DNA damage, compared to exponentially growing culture (Fig-
ure 5). Combined drug-IR treatment under schedule II caused a
strong G2/M block compared to irradiation alone (Table W4).
In summary, our study corroborates the importance of the drug
administration schedule for combined tumor treatment reported
previously [42] and also provides the first evidence that prolonged
treatment of tumor cells with the dual PI3K and mTOR inhibitor
NVP-BEZ235 did not sensitize glioblastoma cell lines to ionizing
radiation. A possible reason could be the drug-mediated activation
of PI3K and mTOR proteins. Yet the observed strong arrest of tumor
cells in the G1 phase justified the use of the substance as a strong
cytostatic drug, which is currently being tested in clinical trials (phases I
to II; www.clinicaltrials.gov). Finally, our in vitro data reveal the
importance of the sequence of drug and IR schedule for the radio-
sensitizing of tumor cells and pave the way for future exploration of
combination of molecularly targeted therapy and radiation on mouse
xenograft tumor models.
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Supplementary Materials
Antibodies
The primary antibodies used were rabbit polyclonal anti-PTEN,
rabbit polyclonal anti-PI3K p110, rabbit polyclonal anti-PI3K p85,
mouse monoclonal anti–phospho-AKT (Ser473), rabbit polyclonal
anti-AKT, rabbit monoclonal anti–phospho-mTOR (Ser2448), rabbit
polyclonal anti-mTOR, rabbit polyclonal anti–phospho-S6 (Ser240/244),
mouse monoclonal anti-S6, mouse monoclonal anti–phospho-4E-
BP1 (all from Cell Signaling Technology, Danvers, MA), mouse
monoclonal anti–β-actin (Sigma, Deisenhofen, Germany), and
mouse monoclonal anti–phospho-histone H2AX (Ser139) fluorescein
isothiocyanate conjugate (Millipore, Schwalbach, Germany). Secondary
species-specific antibodies for Western blot were labeled with HRP
(DAKO, Hamburg, Germany).
Figure W1. Changes of intracellular ATP in glioblastoma cells exposed to serial dilutions of NVP-BEZ235 for 24 and 48 hours. ATP
content was measured by standard luciferase bioluminescence assay. Quadruplicate data derived from at least three independent
experiments were averaged, normalized against non-treated controls (DMSO), and analyzed using the standard 4PLM (Equation 1) to
generate dose-response curves. Error bars indicate SD values. Depicted are the calculated IC50 concentrations.
Table W1. PEs and Radiosensitivity Parameters of Control, Irradiated, and/or Drug-Treated Tumor Cell Lines under Two Different Drug-IR Schedules.
Cell Line Treatment PE* SF2† D10
‡ I10 (D10 Control/D10 NVP-BEZ235)
DK-MG Schedule I Control 0.22 ± 0.06 0.63 ± 0.12 5.73 ± 0.93 1.08 ± 0.18
BEZ235 0.18 ± 0.04 0.58 ± 0.12 5.33 ± 0.73
Schedule II Control 0.17 ± 0.09 0.67 ± 0.09 § 7.93 ± 0.54 § 1.92 ± 0.16
BEZ235 0.16 ± 0.08 0.38 ± 0.05 4.15 ± 0.25
U87-MG Schedule I Control 0.23 ± 0.15 0.54 ± 0.10 5.82 ± 0.35 0.89 ± 0.12
BEZ235 0.18 ± 0.07 0.58 ± 0.04 6.46 ± 0.50
Schedule II Control 0.20 ± 0.08 0.62 ± 0.02 § 8.52 ± 0.39 § 2.1 ± 0.14
BEZ235 0.16 ± 0.09 0.36 ± 0.05 4.06 ± 0.31
GaMG Schedule I Control 0.17 ± 0.04 0.74 ± 0.09 7.69 ± 0.80 1.00 ± 0.05
BEZ235 0.14 ± 0.02 0.79 ± 0.04 7.69 ± 0.61
Schedule II Control 0.17 ± 0.06 0.80 ± 0.08 § 10.21 ± 2.32 § 2.21 ± 0.48
BEZ235 0.17 ± 0.06 0.46 ± 0.08 4.64 ± 0.51
U373 Schedule I Control 0.38 ± 0.18 0.64 ± 0.12 6.01 ± 0.50 0.99 ± 0.11
BEZ235 0.35 ± 0.02 0.59 ± 0.02 6.15 ± 0.83
Schedule II Control 0.29 ± 0.07 0.74 ± 0.08 § 9.01 ± 0.61 § 2.51 ± 0.58
BEZ235 0.30 ± 0.07 0.30 ± 0.09 3.81 ± 1.14
Data are presented as means (±SD) from at least four independent experiments. For detailed description, see legend to Figure 2.
*PE, plating efficiency.
†SF2, surviving fraction at 2 Gy.
‡D10, radiation dose yielding 10% survival; I10, growth inhibition factor was calculated as (D10 control)/D10 + inhibitor).
§≙ < .05.
Figure W2. Effects of NVP-BEZ235 and IR on the expression levels of marker proteins in GaMG (A, C) and U373 (B, D) cell lines detected
30 minutes after IR. Cells were treated with NVP-BEZ235 and IR either in schedule I (left side) or schedule II (right side). For details, see
legend to Figure 3. n.d. indicates not determined.
Figure W3. Effects of NVP-BEZ235 and IR on the expression levels of marker proteins in DK-MG (A, C) and U87-MG (B, D) cell lines
detected 24 and 48 hours after IR. Cells were treated with NVP-BEZ235 and IR either in schedule I (left side) or schedule II (right side).
For details, see legend to Figure 3.
Figure W4. Effects of NVP-BEZ235 and IR on the expression levels of marker proteins in GaMG (A, C) and U373 (B, D) cell lines detected
24 and 48 hours after IR. Cells were treated with NVP-BEZ235 and IR either in schedule I (left side) or schedule II (right side). For details,
see legend to Figure 3.
Figure W5. Effects of NVP-BEZ235 and IR on the late-stage apop-
tosis (subG1 cells). Cells were treatedwith NVP-BEZ235 and IR either
in schedule I or schedule II. For details, see legend to Figure 4.
Figure W6. (A) Effects of NVP-BEZ235 and IR on the induction and repair of DNA damage in DK-MG (A) cell line. Cells were treated with
NVP-BEZ235 and IR either in schedule I (left side) or schedule II (right side). For details, see legend to Figure 5. (B) Effects of NVP-BEZ235
and IR on the induction and repair of DNA damage in U87-MG cell line. Cells were treated with NVP-BEZ235 and IR either in schedule I
(left side) or schedule II (right side). For details, see legend to Figure 5. (C) Effects of NVP-BEZ235 and IR on the induction and repair of
DNA damage in U373 cell line. Cells were treated with NVP-BEZ235 and IR either in schedule I (left side) or schedule II (right side). For
details, see legend to Figure 5.
Figure W6. (continued).
Table W2. Cell Cycle Phase Distribution in Tumor Cells Treated with NVP-BEZ235 and IR according to Different Schedules.
Cell Line Treatment Modality G0/G1 (%) S (%) G2/M (%) G2/G1
DK-MG Schedule I 0 Gy Control 53 ± 4 22 ± 3 26 ± 3 0.49
NVP-BEZ235 73 ± 2 9 ± 2 18 ± 2 0.25
8 Gy Control 54 ± 3 21 ± 3 25 ± 3 0.46
NVP-BEZ235 74 ± 2 10 ± 2 17 ± 2 0.23
Schedule II 0 Gy Control 46 ± 4 28 ± 3 26 ± 3 0.57
NVP-BEZ235 45 ± 4 29 ± 5 26 ± 3 0.58
8 Gy Control 46 ± 4 28 ± 3 26 ± 4 0.57
NVP-BEZ235 46 ± 5 28 ± 3 26 ± 4 0.57
U87-MG Schedule I 0 Gy Control 70 ± 3 20 ± 3 10 ± 2 0.14
NVP-BEZ235 90 ± 4 6 ± 2 5 ± 2 0.06
8 Gy Control 71 ± 3 19 ± 2 10 ± 4 0.14
NVP-BEZ235 89 ± 3 6 ± 1 5 ± 2 0.06
Schedule II 0 Gy Control 51 ± 8 28 ± 3 22 ± 6 0.43
NVP-BEZ235 51 ± 9 28 ± 3 21 ± 6 0.41
8 Gy Control 49 ± 9 29 ± 4 22 ± 7 0.45
NVP-BEZ235 50 ± 9 28 ± 4 22 ± 6 0.44
GaMG Schedule I 0 Gy Control 60 ± 6 28 ± 4 12 ± 4 0.20
NVP-BEZ235 80 ± 3 11 ± 4 9 ± 4 0.11
8 Gy Control 61 ± 7 27 ± 5 12 ± 5 0.20
NVP-BEZ235 79 ± 3 13 ± 5 8 ± 3 0.10
Schedule II 0 Gy Control 40 ± 12 34 ± 11 26 ± 16 0.65
NVP-BEZ235 41 ± 11 36 ± 11 23 ± 16 0.56
8 Gy Control 40 ± 12 35 ± 12 25 ± 16 0.63
NVP-BEZ235 42 ± 11 33 ± 16 24 ± 18 0.57
U373 Schedule I 0 Gy Control 67 ± 6 17 ± 3 16 ± 5 0.25
NVP-BEZ235 65 ± 11 19 ± 7 16 ± 4 0.25
8 Gy Control 65 ± 5 18 ± 3 17 ± 5 0.26
NVP-BEZ235 62 ± 10 21 ± 6 17 ± 5 0.27
Schedule II 0 Gy Control 36 ± 8 37 ± 13 28 ± 10 0.78
NVP-BEZ235 38 ± 10 37 ± 13 25 ± 11 0.66
8 Gy Control 39 ± 9 36 ± 13 25 ± 9 0.64
NVP-BEZ235 38 ± 10 37 ± 13 24 ± 11 0.63
Thirty minutes after IR, cells were fixed, permeabilized, stained with PI, and analyzed for DNA content by flow cytometry.
Data are presented as means (±SD) from at least four independent experiments. For detailed description, see legend to Figure 6.
Table W3. Cell Cycle Phase Distribution in Tumor Cells Treated with NVP-BEZ235 and IR according to Different Schedules.
Cell Line Treatment Modality G0/G1 (%) S (%) G2/M (%) G2/G1
DK-MG Schedule I 0 Gy Control 49 ± 3 24 ± 4 27 ± 3 0.55
NVP-BEZ235 49 ± 9 26 ± 4 25 ± 6 0.51
8 Gy Control 21 ± 4 8 ± 1 71 ± 4 3.38
NVP-BEZ235 22 ± 12 31 ± 4 47 ± 12 2.14
Schedule II 0 Gy Control 55 ± 6 22 ± 2 23 ± 6 0.42
NVP-BEZ235 74 ± 6 9 ± 2 17 ± 6 0.23
8 Gy Control 29 ± 13 9 ± 3 63 ± 16 2.17
NVP-BEZ235 27 ± 16 11 ± 3 62 ± 13 2.30
U87-MG Schedule I 0 Gy Control 71 ± 3 18 ± 2 10 ± 1 0.14
NVP-BEZ235 67 ± 3 20 ± 4 14 ± 2 0.21
8 Gy Control 58 ± 6 10 ± 1 32 ± 5 0.55
NVP-BEZ235 56 ± 8 19 ± 4 25 ± 6 0.45
Schedule II 0 Gy Control 68 ± 8 20 ± 2 12 ± 6 0.18
NVP-BEZ235 85 ± 7 9 ± 2 6 ± 6 0.07
8 Gy Control 59 ± 14 9 ± 1 33 ± 15 0.56
NVP-BEZ235 58 ± 17 4 ± 3 37 ± 15 0.64
GaMG Schedule I 0 Gy Control 73 ± 7 18 ± 5 9 ± 3 0.12
NVP-BEZ235 50 ± 14 26 ± 5 24 ± 4 0.48
8 Gy Control 65 ± 6 17 ± 4 17 ± 4 0.26
NVP-BEZ235 27 ± 9 22 ± 5 51 ± 9 1.89
Schedule II 0 Gy Control 62 ± 4 28 ± 3 11 ± 3 0.18
NVP-BEZ235 79 ± 6 12 ± 5 9 ± 2 0.11
8 Gy Control 55 ± 12 26 ± 4 19 ± 6 0.35
NVP-BEZ235 40 ± 8 12 ± 4 47 ± 8 1.18
U373 Schedule I 0 Gy Control 67 ± 7 12 ± 2 21 ± 5 0.31
NVP-BEZ235 62 ± 5 15 ± 2 23 ± 3 0.37
8 Gy Control 57 ± 8 8 ± 3 35 ± 6 0.61
NVP-BEZ235 37 ± 8 14 ± 3 49 ± 8 1.32
Schedule II 0 Gy Control 64 ± 5 18 ± 4 19 ± 3 0.30
NVP-BEZ235 59 ± 5 24 ± 3 17 ± 2 0.29
8 Gy Control 60 ± 5 10 ± 2 30 ± 6 0.50
NVP-BEZ235 24 ± 27 12 ± 5 64 ± 27 2.67
Twenty-four hours after IR, cells were fixed, permeabilized, stained with PI, and analyzed for DNA content by flow cytometry.
Data are presented as means (±SD) from at least four independent experiments. For detailed description, see legend to Figure 6.
Table W4. Cell Cycle Phase Distribution in Tumor Cells Treated with NVP-BEZ235 and IR according to Different Schedules.
Cell Line Treatment Modality G0/G1 (%) S (%) G2/M (%) G2/G1
DK-MG Schedule I 0 Gy Control 56 ± 4 20 ± 2 24 ± 3 0.43
NVP-BEZ235 66 ± 7 13 ± 5 20 ± 4 0.30
8 Gy Control 39 ± 4 24 ± 2 37 ± 3 0.95
NVP-BEZ235 53 ± 6 7 ± 3 41 ± 6 0.77
Schedule II 0 Gy Control 53 ± 4 23 ± 7 24 ± 6 0.45
NVP-BEZ235 72 ± 3 10 ± 4 18 ± 2 0.25
8 Gy Control 37 ± 3 23 ± 3 40 ± 3 1.08
NVP-BEZ235 26 ± 9 10 ± 6 64 ± 8 2.46
U87-MG Schedule I 0 Gy Control 71 ± 3 19 ± 2 10 ± 2 0.14
NVP-BEZ235 70 ± 3 19 ± 2 11 ± 3 0.16
8 Gy Control 59 ± 2 17 ± 2 24 ± 2 0.41
NVP-BEZ235 68 ± 3 14 ± 3 18 ± 3 0.26
Schedule II 0 Gy Control 69 ± 3 21 ± 3 11 ± 2 0.16
NVP-BEZ235 82 ± 2 12 ± 1 6 ± 2 0.07
8 Gy Control 54 ± 2 20 ± 2 27 ± 2 0.50
NVP-BEZ235 55 ± 2 8 ± 2 37 ± 1 0.67
GaMG Schedule I 0 Gy Control 87 ± 4 5 ± 3 8 ± 2 0.09
NVP-BEZ235 81 ± 4 10 ± 3 10 ± 2 0.12
8 Gy Control 66 ± 8 12 ± 6 22 ± 4 0.33
NVP-BEZ235 65 ± 4 18 ± 4 17 ± 3 0.26
Schedule II 0 Gy Control 77 ± 8 12 ± 5 11 ± 3 0.14
NVP-BEZ235 80 ± 5 10 ± 3 10 ± 3 0.13
8 Gy Control 55 ± 6 21 ± 6 25 ± 6 0.45
NVP-BEZ235 40 ± 7 11 ± 4 49 ± 9 1.23
U373 Schedule I 0 Gy Control 82 ± 4 8 ± 2 10 ± 3 0.12
NVP-BEZ235 79 ± 4 9 ± 2 12 ± 2 0.15
8 Gy Control 62 ± 8 16 ± 4 22 ± 5 0.35
NVP-BEZ235 64 ± 5 15 ± 4 21 ± 3 0.33
Schedule II 0 Gy Control 70 ± 3 14 ± 2 16 ± 2 0.23
NVP-BEZ235 68 ± 2 16 ± 2 16 ± 1 0.24
8 Gy Control 38 ± 5 22 ± 3 40 ± 4 1.05
NVP-BEZ235 12 ± 5 14 ± 2 74 ± 6 6.17
Forty-eight hours after IR, cells were fixed, permeabilized, stained with PI, and analyzed for DNA content by flow cytometry.
Data are presented as means (±SD) from at least four independent experiments. For detailed description, see legend to Figure 6.
